SCHEMBL19762845

SCHEMBL19762845

CNc1cn2c(-c3ccccc3)cccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 10/20 0.46
CHEK1 O14757 3/20 0.46
MAP4K4 O95819 1/20 0.46
CSF1R P07333 1/20 0.46
PRKACA P17612 1/20 0.46
KDR P35968 1/20 0.46
CDK8 P49336 1/20 0.46
MAP2K1 Q02750 1/20 0.46
ACVR1 Q04771 1/20 0.46
MAP4K2 Q12851 1/20 0.46
ROCK1 Q13464 1/20 0.46
DYRK1A Q13627 1/20 0.46
AURKB Q96GD4 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
JAK2 O60674 3/20 0.41
TYK2 P29597 2/20 0.41
NUDT1 P36639 1/20 0.41
EGLN2 Q96KS0 1/20 0.39
ATM Q13315 1/20 0.38
PDE10A Q9Y233 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21377621 0.84 CHEK1 (0.46) JAK1CHEK1MAP4K4CSF1RPRKACA
SCHEMBL12920622 0.78 CHEK1 (0.50) JAK1CHEK1MAP4K4CSF1RPRKACA
SCHEMBL19762842 0.75 JAK1 (0.75) JAK1JAK2TYK2
Hydrochloric Acid SCHEMBL28842780 0.75 RAB9A (0.44) PDE10AMAPT
SCHEMBL19762844 0.74 CHEK1 (0.46) JAK1CHEK1MAP4K4CSF1RPRKACA
SCHEMBL27675710 0.74 CHEK1 (0.46) JAK1CHEK1MAP4K4CSF1RPRKACA
SCHEMBL28842816 0.72 JAK1 (0.41) JAK1MAP4K4CSF1RPRKACAKDR
SCHEMBL100904 0.71 CHEK1 (0.46) JAK1CHEK1MAP4K4CSF1RPRKACA
SCHEMBL103694 0.71 NUDT1 (0.47) JAK1CHEK1MAP4K4CSF1RPRKACA
SCHEMBL30827265 0.71 TGFBR1 (0.35) JAK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024511-B2 Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) 2024-07-02 US disclosed
US-20180002328-A1 SUBSTITUTED IMIDAZO[1, 2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF JN THERAPEUTICS LTD. (CN) 2018-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024511-B2 Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof JAK1, JAK2, JAK3 JAK1 1/4885CHEK1 615/4885MAP4K4 49/4885
US-20180002328-A1 SUBSTITUTED IMIDAZO[1, 2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF JAK1, JAK2, JAK3 JAK1 1/4885CHEK1 615/4885MAP4K4 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.